Overview

NCI Definition: A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells. When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia. When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001) [1]

T-cell lymphoblastic leukemia/lymphomas most frequently harbor alterations in NOTCH1 [2].

Most Commonly Altered Genes in T-Cell Lymphoblastic Leukemia/Lymphoma

NOTCH1 Mutation and NOTCH1 Missense are the most common alterations in T-cell lymphoblastic leukemia/lymphoma [2].

Top Alterations in T-Cell Lymphoblastic Leukemia/Lymphoma

Significant Genes in T-Cell Lymphoblastic Leukemia/Lymphoma

ABL1 +

ABL2 +

AFF1 +

BCR +

CRLF2 +

CSF1R +

DEK +

ELL +

EPOR +

FLT3 +

IL7R +

JAK1 +

JAK2 +

JAK3 +

KMT2A +

MECOM +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

NPM1 +

NUP214 +

PBX1 +

PDGFRB +

RPN1 +

SH2B3 +

TCF3 +

TP53 +

Disease Details

Synonyms
T-Lymphoblastic Leukemia/Lymphoma, PEDIATRIC T-lymphoblastic leukemia-lymphoma (T-ALL), T-lymphoblastic leukemia-lymphoma (T-ALL), Precursor T-Lymphoblastic Lymphoma/Leukemia, Precursor T Lymphoblastic Lymphoma/Leukemia, T Lymphoblastic Leukemia/Lymphoma, Precursor T Lymphoblastic Leukemia/Lymphoma
Parent(s)
Precursor Lymphoid Neoplasm
Children
T-Cell Lymphoblastic Lymphoma, T-Cell Acute Lymphoblastic Leukemia, Refractory T-Cell Lymphoblastic Leukemia/Lymphoma, Mediastinal T Lymphoblastic Lymphoma, and Childhood T-Cell Lymphoblastic Leukemia/Lymphoma
OncoTree Name
T-Lymphoblastic Leukemia/Lymphoma
OncoTree Code
TLL

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.